Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

Bristol-Myers Squibb (BMS) building

BMS pens massive $3.6bn deal for Nektar cancer immunotherapy

Nektar’s NKTR-214 to be paired with Opdivo and Yervoy in a host of tumour types

- PMLiVE

Trio of new starters for Wave

Lucy Noble, Ella Withey and Maria Cain join the UK med ed agency

- PMLiVE

McCann Health appoints Daniel Carucci as global medical director

The newly-created position will see him work across McCann's global network

Finding the patient voice

How patients feel and speak about clinical trials

Six Degrees Medical

Six Degrees Medical Consulting

- PMLiVE

Another Alzheimer’s bust as Merck & Co stops verubecestat study

Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai

- PMLiVE

Vertex’s two-drug cystic fibrosis treatment cleared in US

FDA approves Symdeko, which combines Kalydeco and tezacaftor

- PMLiVE

Trio of senior hires joins Syneos Health

Nicky Walsby, Andrew Thomas and Ellie Duncanson-Hunter appointed to its European leadership team

- PMLiVE

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

- PMLiVE

After Axovant shock, Roivant pens diabetes deal with Poxel

Acquires Merck Serono’s diabetes candidate imeglimin as part of the deal

- PMLiVE

Eleven Magical Years for Lucid Group

Lucid Group celebrated their eleventh birthday today. They served up plenty of cake and excitement, distributing invitations for family and friends to attend the Lucid Magic festival, which is being...

Lucid Group Communications Limited

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links